Horm Metab Res 2019; 51(02): 100-105
DOI: 10.1055/a-0749-6431
Endocrine Care

The Effect of Magnesium and Vitamin E Co-Supplementation on Glycemic Control and Markers of Cardio-Metabolic Risk in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

Mehri Jamilian
1   Endocrinology and Metabolism Research Center, Arak University of Medical Sciences, Arak, Iran
Niloufar Kazemi Sabzevar
1   Endocrinology and Metabolism Research Center, Arak University of Medical Sciences, Arak, Iran
Zatollah Asemi
2   Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran
› Author Affiliations


Data on the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk of patients with polycystic ovary syndrome (PCOS) were collected. This investigation was conducted to evaluate the effects of magnesium and vitamin E co-supplementation on glycemic control and markers of cardio-metabolic risk in women with PCOS. This randomized, double-blind, placebo-controlled trial was carried out on 60 women with PCOS, aged 18–40 years old. Participants were randomly divided into two groups to receive 250 mg/day magnesium plus 400 mg/day vitamin E supplements or placebo (n=30 each group) for 12 weeks. Fasting blood samples were taken at baseline and after the 12-week intervention to quantify related variables. After the 12-week intervention, compared with the placebo, magnesium and vitamin E co-supplementation led to a significant reduction in serum insulin levels (–1.1±3.0 vs. +1.6±3.7 μIU/ml, p=0.003) and homeostatic model of assessment for insulin resistance (–0.2±0.7 vs. +0.4±0.9, p=0.002), and a significant increase in the quantitative insulin sensitivity check index (+0.01±0.01 vs. –0.009±0.02, p=0.003). Furthermore, magnesium plus vitamin E supplementation significantly decreased serum triglycerides (–15.0±24.4 vs. +6.7±22.2 mg/dl, p=0.001) and VLDL-cholesterol concentrations (–3.0±4.9 vs. +0.6±2.4 mg/dl, P=0.01) compared with the placebo. A trend toward a greater decrease in total cholesterol levels was observed in magnesium plus vitamin E group compared to placebo group (–7.0±32.6 vs. +8.1±26.6 mg/dl, p=0.05). In conclusion, magnesium and vitamin E co-supplementation for 12 weeks to PCOS women had beneficial effects on parameters of insulin metabolism and few markers of cardio-metabolic risk.

Publication History

Received: 28 March 2018

Accepted: 17 September 2018

Article published online:
04 October 2018

© 2018. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers 2016; 2: 16057
  • 2 Moghetti P. Insulin resistance and polycystic ovary syndrome. Curr Pharm Des 2016; 22: 5526-5534
  • 3 Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-1935
  • 4 Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84: 165-169
  • 5 Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2014; 99: E447-E452
  • 6 Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. Metabolism 2018; 86: 33-43
  • 7 Chakraborty P, Ghosh S, Goswami SK, Kabir SN, Chakravarty B, Jana K. Altered trace mineral milieu might play an aetiological role in the pathogenesis of polycystic ovary syndrome. Biol Trace Elem Res 2013; 152: 9-15
  • 8 Zhang D, Luo WY, Liao H, Wang CF, Sun Y. [The effects of oxidative stress to PCOS]. Sichuan Da Xue Xue Bao Yi Xue Ban 2008; 39: 421-423
  • 9 Jamilian M, Maktabi M, Asemi Z. A Trial on The effects of magnesium-zinc-calcium-vitamin D co-supplementation on glycemic control and markers of cardio-metabolic risk in women with polycystic ovary syndrome. Arch Iran Med 2017; 20: 640-645
  • 10 Veronese N, Watutantrige-Fernando S, Luchini C, Solmi M, Sartore G, Sergi G, Manzato E, Barbagallo M, Maggi S, Stubbs B. Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: A systematic review and meta-analysis of double-blind randomized controlled trials. Eur J Clin Nutr 2016; 70: 1354-1359
  • 11 Rafraf M, Bazyun B, Sarabchian MA, Safaeiyan A, Gargari BP. Vitamin E Improves serum paraoxonase-1 activity and some metabolic factors in patients with type 2 diabetes: No effects on nitrite/nitrate levels. J Am Coll Nutr 2016; 35: 521-528
  • 12 Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G. Effects of vitamin E and glutathione on glucose metabolism: Role of magnesium. Hypertension 1999; 34: 1002-1006
  • 13 Dou M, Ma AG, Wang QZ, Liang H, Li Y, Yi XM, Zhang SC. Supplementation with magnesium and vitamin E were more effective than magnesium alone to decrease plasma lipids and blood viscosity in diabetic rats. Nutr Res 2009; 29: 519-524
  • 14 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25
  • 15 Pisprasert V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT. Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: Impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care 2013; 36: 845-853
  • 16 Asemi Z, Karamali M, Jamilian M, Foroozanfard F, Bahmani F, Heidarzadeh Z, Benisi-Kohansal S, Surkan PJ, Esmaillzadeh A. Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: A randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2015; 102: 222-229
  • 17 Bargiota A, Diamanti-Kandarakis E. The effects of old, new and emerging medicines on metabolic aberrations in PCOS. Ther Adv Endocrinol Metab 2012; 3: 27-47
  • 18 Lee S, Park HK, Son SP, Lee CW, Kim IJ, Kim HJ. Effects of oral magnesium supplementation on insulin sensitivity and blood pressure in normo-magnesemic nondiabetic overweight Korean adults. Nutr Metab Cardiovasc Dis 2009; 19: 781-788
  • 19 Khatami PG, Soleimani A, Sharifi N, Aghadavod E, Asemi Z. The effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy: A randomized, double-blind, placebo-controlled trial. J Clin Lipidol 2016; 10: 922-929
  • 20 Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: Analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005; 27: 1930-1941
  • 21 Bloomgarden ZT. Second world congress on the insulin resistance syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care 2005; 28: 1821-1830
  • 22 Kowluru A, Chen HQ, Modrick LM, Stefanelli C. Activation of acetyl-CoA carboxylase by a glutamate- and magnesium-sensitive protein phosphatase in the islet beta-cell. Diabetes 2001; 50: 1580-1587
  • 23 Murakami M, Ishizuka J, Sumi S, Nickols GA, Cooper CW, Townsend Jr CM, Thompson JC. Role of extracellular magnesium in insulin secretion from rat insulinoma cells. Proc Soc Exp Biol Med 1992; 200: 490-494
  • 24 Lee JE, Han JY, Choi JS, Ahn HK, Lee SW, Kim MH, Ryu HM, Yang JH, Nava-Ocampo AA, Koren G. Pregnancy outcome after exposure to the probiotic Lactobacillus in early pregnancy. J Obstet Gynaecol 2012; 32: 227-229
  • 25 Rodriguez-Moran M, Guerrero-Romero F. Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: A randomized double-blind placebo-controlled trial. Arch Med Res 2014; 45: 388-393
  • 26 Lal J, Vasudev K, Kela AK, Jain SK. Effect of oral magnesium supplementation on the lipid profile and blood glucose of patients with type 2 diabetes mellitus. J Assoc Physicians India 2003; 51: 37-42
  • 27 de Castro-Sobrinho JM, Rabelo-Santos SH, Fugueiredo-Alves RR, Derchain S, Sarian LO, Pitta DR, Campos EA, Zeferino LC. Bacterial vaginosis and inflammatory response showed association with severity of cervical neoplasia in HPV-positive women. Diagn Cytopathol 2016; 44: 80-86
  • 28 Kim DY, Kim J, Ham HJ, Choue R. Effects of d-alpha-tocopherol supplements on lipid metabolism in a high-fat diet-fed animal model. Nutr Res Pract 2013; 7: 481-487
  • 29 Kishimoto Y, Tani M, Uto-Kondo H, Saita E, Iizuka M, Sone H, Yokota K, Kondo K. Effects of magnesium on postprandial serum lipid responses in healthy human subjects. Br J Nutr 2010; 103: 469-472
  • 30 Rayssiguier Y, Gueux E. Magnesium and lipids in cardiovascular disease. J Am Coll Nutr 1986; 5: 507-519
  • 31 Ryu OH, Chung W, Lee S, Hong KS, Choi MG, Yoo HJ. The effect of high-dose vitamin D supplementation on insulin resistance and arterial stiffness in patients with type 2 diabetes. Korean J Intern Med 2014; 29: 620-629